Kenya Launches New 6-Month Injectable HIV Treatment

Kenya has initiated a phased rollout of Lenacapavir, a long-acting injectable medicine for HIV prevention. The government’s action marks a significant advancement in the nation’s public health strategy and places Kenya among nine African countries pioneering this innovation.

The introduction of Lenacapavir aims to address challenges associated with daily oral pre-exposure prophylaxis (PrEP), including stigma and adherence difficulties. The medicine, approved by the US Food and Drug Administration (FDA) and endorsed by the World Health Organization (WHO), has demonstrated 100% efficacy in some clinical trials.

The Science of Lenacapavir

Lenacapavir offers a departure from the traditional daily pill regimen for HIV prevention. The twice-yearly injection eliminates the need for daily adherence and provides a discreet method of protection. A senior Ministry of Health official described the medicine as removing the daily decision-making process from prevention, offering protection for six months.

Rollout Strategy

The Ministry of Health is implementing a phased rollout supported by funding from the Global Fund. The initial phase will focus on high-risk populations and areas with high HIV prevalence rates. Priority demographics include adolescent girls, young women, and key populations who have historically faced barriers to accessing daily PrEP.

While the branded drug has a high cost in the United States, Kenya has secured access through generic licensing agreements and donor subsidies, making it sustainable for the public health system. Kenya joins Eswatini, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe in a collaborative effort to establish a prevention network across Sub-Saharan Africa.

Addressing Stigma

The sociological impact of Lenacapavir is expected to be significant. In some Kenyan communities, the visibility of taking daily antiretroviral pills can lead to social stigma. The injection, administered privately in a clinic every six months, offers a more discreet option, potentially empowering users and reducing the risk of judgment or violence.

The arrival of Lenacapavir in clinics across Kenya has been met with cautious optimism within the medical community. While not a cure, the medicine represents a substantial advancement in HIV prevention efforts, offering hope for reducing transmission after four decades of battling the epidemic.